Nektar Therapeutics(NKTR) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Oppenheimer Upgrades Nektar Therapeutics(NKTR.US) to Buy Rating, Announces Target Price $6
Moomoo NewsMar 15 01:31 ET · Ratings
Nektar Therapeutics | 10-K: FY2024 Annual Report
SECMar 14 16:03 ET · Announcements
Nektar Therapeutics Shares Rise After Upgrade From Oppenheimer
MT NewswiresMar 14 14:53 ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
BenzingaMar 14 08:10 ET
Oppenheimer Upgrades Nektar Therapeutics to Outperform From Market Perform, Price Target Is $6
MT NewswiresMar 14 07:20 ET · Ratings
Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)
Zacks Mar 14 07:05 ET

Comments

Teddy123

Mar 14 21:30

Nektar upgraded at Oppenheimer on upcoming mid-stage trial readout

$Nektar Therapeutics (NKTR.US)$

Teddy123

Mar 13 10:26

Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

$Nektar Therapeutics (NKTR.US)$
Nektar Therapeutics Achieves Surprise Q4 Profit as Revenue Jumps 22%

Teddy123

Feb 26 20:11

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata

$Nektar Therapeutics (NKTR.US)$
Can Nektar's T-cell Therapy Revolutionize Alopecia Treatment? Phase 2b Trial Fully Enrolled

Jaguar8

Feb 26 20:05

NEWS

$Nektar Therapeutics (NKTR.US)$
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata
Wednesday, 26th February at 7:00 am
SAN FRANCISCO, Feb. 26, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced the company has completed target enrollment in its REZOLVE-AA Phase 2b study of rezpegaldesleukin in patients with severe-to-very-severe alopecia areata.
Re...

Teddy123

Feb 24 21:04

Medical Research analysis

$Nektar Therapeutics (NKTR.US)$
This Phase 2 trial announcement represents a strategic advancement in Nektar's development of rezpegaldesleukin for type 1 diabetes treatment. The collaboration with TrialNet, a leading international diabetes research network, significantly enhances the trial's credibility and execution potential. The study's design is particularly robust, incorporating both mixed meal tolerance testing and C-peptide preservation measurements - important ma...

NKTR Nektar Therapeutics

Trade Overview

Capital Trend

News

Comments

Trending Stocks